NTAGI

NTAGI to review trial data on Serum Institute's qHPV vaccine against cervical cancer

A separate HPV working group of the National Technical Advisory Group on Immunisation (NTAGI) had examined on June 8 the clinical trial data and usefulness of the vaccine.

published on : 26th June 2022

NTAGI sub panel recommends reducing Covid booster dose gap to six months

The panel members found a lack of uniformity in results upon mixing of jabs for booster shots and stated that no recommendation for it can be made as of now.

published on : 16th June 2022

NTAGI to discuss allowing Corbevax as booster for those vaccinated with Covishield, Covaxin: Sources

The Drugs Controller General of India (DCGI) on Sunday approved Corbevax for the precaution dose for those aged 18 and above.

published on : 7th June 2022

NTAGI endorses precaution dose before nine-month waiting period for those travelling abroad: Sources

However, no recommendation as of now has been made by the National Technical Advisory Group on Immunisation (NTAGI) over reducing the gap between the second dose and the precaution jab.

published on : 6th May 2022

First dose to be given as booster to those jabbed with Sputnik V: Advisory Panel 

The Union health ministry also announced that India’s vaccination coverage had crossed the 189 crore landmark milestone on Saturday.

published on : 30th April 2022

Advisory Group recommends Covovax for 12-17 children; no decision yet on vaccinating kids below 12 

India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 last year and in the 12-17 age group.

published on : 29th April 2022

Second Covishield dose can be given between 8-16 weeks after first: NTAGI

The NTAGI has not yet suggested any change in the schedule of Bharat Biotech's Covaxin, whose second dose is administered 28 days after the first dose.

published on : 20th March 2022

Vaccination of 12-14-year age group: No nod sought for Corbevax, says NTAGI

In the process of vaccine approvals, after the DCGI’s nod, the NTAGI deliberates on this and screens the ability of the vaccine to be part of the national vaccination drive at a three-level process.  

published on : 17th March 2022

Corbevax’s immune response is superior, says Biological E

The company has produced 30 crore doses of the same and has supplied five crore doses to the government of India.

published on : 17th March 2022

COVID-19: Expert opinion divided over vaccinating children of 12-14 age group

Top epidemiologist Dr JP Muliyil said the government's decision to allow vaccination of this group from Wednesday will not 'benefit them' and the move is yet to get approval from NTAGI.

published on : 16th March 2022

Expert panel ponders upon restructuring of COVID vaccines against Omicron

NK Arora, head of COVID Working Group of the NTAGI, told that daily deliberations are on whether the existing vaccines in India can be specifically tailored against Omicron.

published on : 9th January 2022

No need to vaccinate children against Covid-19 now, says advisory group; Omicron cases cross 200 in India

The panel has informed the Centre that the children are doing fine and there is no need to vaccinate them now.

published on : 21st December 2021